First prescriptions delivered to individuals with PWSREDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno ...

Prescriptions of VYKAT XR have now been delivered to the first individuals living with PWS who have been prescribed the medication. “We are extremely pleased to begin delivering VYKAT XR ...

Soleno Therapeutics (SLNO) announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for ...

Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company with a market capitalization of $3.08 billion, announced today the U.S. commercial availability of VYKAT XR, an FDA-approved ...

REDWOOD CITY, Calif. - Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company with a market capitalization of $3.08 billion, announced today the U.S. commercial availability of VYKAT XR ...

Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...

Soleno Therapeutics (NASDAQ:SLNO) has gained attention following the FDA approval of its VYKAT XR treatment for hyperphagia in patients with Prader-Willi syndrome. The company is well-positioned ...

Soleno Therapeutics (NASDAQ:SLNO) has gained attention following the FDA approval of its VYKAT XR treatment for hyperphagia in patients with Prader-Willi syndrome. The company is well-positioned for a ...